🔴 Bristol-Myers Squibb Company is trading 4.3% down today as investors lock in gains following EU Opdivo combo approval

Bristol-Myers Squibb Company is trading 4.3% down at $54.70 today as investors lock in gains following a rally driven by positive regulatory news.

• The stock had surged on May 31, 2026, after the European Commission approved Opdivo plus AVD as the first immunotherapy-based combination for first-line Stage III/IV classical Hodgkin lymphoma.
• Shares are currently pulling back as the market reassesses valuation following the initial catalyst-driven run-up.